TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Rutgers-led study of U.S. adults with Type 2 diabetes found GLP-1 medications, including semaglutide and tirzepatide, were associated with a small increase in a rare condition that can cause sudden vision loss. Researchers estimated about three to four additional cases per 10,000 treated patients over 18 months, but said the study does not show the drugs directly cause the condition.
A Rutgers-led study found that adults with Type 2 diabetes who used GLP-1 medications, including Ozempic and Wegovy, had a modestly higher likelihood of ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The study, published in Annals of Internal Medicine, estimated about three to four additional cases per 10,000 treated patients over 18 months; it does not establish that the medicines caused the condition.
The researchers analyzed health information from a large U.S. database covering adults ages 18 to 65 with Type 2 diabetes who had recently started medication to manage the disease. They compared people using GLP-1 receptor agonists with patients taking other diabetes medicines. The drug class includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound.
Ischemic optic neuropathy occurs when reduced blood flow damages the optic nerve, which carries visual information from the eye to the brain. The study found an association between GLP-1 use and a modest increase in the condition’s likelihood, but the number of cases remained low. Chintan Dave, the study’s lead author and a Rutgers researcher, said the estimate was roughly three to four extra cases per 10,000 patients treated over 18 months.
Cases were more common among men and people in the older part of the study’s age range, according to the researchers. Sudden blurring, dimming or missing areas in one eye’s field of vision can occur. The study report notes that vision loss may be permanent, although some patients experience partial recovery. These findings describe patterns in the study population and do not establish which individual patients will develop the condition.
A Small Risk With Serious Consequences
The result draws attention to a possible safety signal for medicines used widely to manage Type 2 diabetes and weight. The study authors described the absolute increase as small, but the outcome can affect vision and may be lasting. That makes the finding relevant to patients and clinicians weighing treatment benefits and risks, without showing that most people taking the drugs face a substantial chance of this complication.
GLP-1 medicines can help control blood sugar and manage weight, and have been associated with lower risks of some cardiovascular and kidney problems, according to the source report. The new finding does not overturn those established treatment uses or provide a reason for patients to stop medication on their own. It adds a possible risk for further study and supports attention to sudden vision changes, especially among people who may already have higher baseline risk.
As an affiliate, we earn on qualifying purchases.
What the Study Examined
The study focused on adults with Type 2 diabetes who had recently begun treatment, rather than all users of weight-loss medicines. Its findings concern an association observed in health records; they do not prove that a GLP-1 drug caused optic nerve damage. Differences in patients’ health, underlying conditions or other factors could help explain the observed pattern.
The condition discussed is ischemic optic neuropathy. The source report says more than 80% of cases are estimated to involve its non-arteritic anterior form, in which blood supply to the front of the optic nerve becomes insufficient. It can affect part of the vision in one eye rather than causing complete blindness. Dave said about one-third of affected patients experience some recovery, usually within six months, while some visual impairment typically remains.
“Although ischemic optic neuropathy was rare, it is clinically important because it can involve sudden vision loss.”
— Chintan Dave, Rutgers study lead author
As an affiliate, we earn on qualifying purchases.
Causation and Individual Risk Remain Open
The study does not show that semaglutide, tirzepatide or other GLP-1 medicines directly cause ischemic optic neuropathy. The researchers said differences in patients’ underlying health and other factors could account for some or all of the association. Further research is needed to test whether the medicines themselves contribute to the condition.
The source report does not provide the database’s exact patient count, the full comparison-group details, or enough information to calculate a person’s individual risk. It also does not establish whether the finding applies to people without Type 2 diabetes, even though GLP-1 medicines are prescribed to some people in that group. The reported rate is an estimate for the study population and timeframe, not a forecast for every user.
As an affiliate, we earn on qualifying purchases.
Further Safety Research Needed
The researchers say additional studies are needed to clarify whether GLP-1 drugs contribute to the condition and how much of the observed association may reflect other health differences. Continued safety monitoring will matter as use of the medicines expands. The source material does not identify a planned follow-up study or a change to prescribing guidance.
For people taking these medicines, the report’s immediate practical point is to treat sudden changes in vision as a reason for prompt medical assessment. It does not advise patients to stop treatment. Anyone considering a medication change should discuss it with a qualified health professional, who can weigh their circumstances and treatment options.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does the study prove Ozempic or Wegovy causes sudden vision loss?
No. The study found an association between GLP-1 medication use and ischemic optic neuropathy, but it did not establish that the drugs directly cause optic nerve damage. Other health differences could help explain the result.
How large was the estimated increase?
The researchers estimated about three to four additional cases per 10,000 treated patients over 18 months. The source describes this as a small increase, and the estimate applies to the population studied.
What symptoms were described?
The condition can involve sudden blurring, dimming or missing areas in the field of vision, often affecting part of the vision in one eye. Sudden vision changes should be assessed promptly by a medical professional.
Should patients stop taking GLP-1 medicines?
The study report does not advise patients to stop their medication. Anyone concerned about the finding or considering a change should discuss their treatment with a qualified health professional.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
